

Supplemental table

Table S1: Characteristics of Patients Who Completed and Those Who Did Not Complete the SGRQ^a

Characteristics	All patients (N = 3574)	Patients completing the SGRQ (n = 2407)	Patients not completing the SGRQ (n = 1167)
Age at enrollment, years			
Mean (SD)	54.4 (14.7)	54.0 (14.4)	55.3 (15.4)
Median (range)	56 (18–94)	56 (18–92)	57 (18–94)
Female, %	68.7	70.1	65.8
Body mass index (kg/m ²), mean (SD)	33.2 (8.9)	33.2 (9.0)	33.1 (8.6)
Race, %			
White	73.5	77.5	65.1
Black	17.6	14.9	23.1
Asian	1.8	1.6	2.1
Other ^b	3.2	3.4	2.7
Not reported	3.9	2.5	6.6
Missing	0.1	0.0	0.4
Hispanic or Latino ethnicity, %	10.0	9.1	12.1
Residential area			
Urban	26.6	25.3	29.0
Rural	22.9	23.4	21.9
Suburban	47.3	48.4	45.0
Missing	3.0	2.8	3.4
Insurance, %			
Commercial	57.4	60.3	51.4
Medicaid	11.2	10.1	13.4
Medicare	23.5	21.6	27.4
Uninsured	1.0	1.0	0.9
Other ^c	6.9	6.9	6.7
Missing	0.1	0.0	0.2
Employment status, %			
Employed (full-time, part-time, or self-employed)	47.3	49.6	42.4
Homemaker	3.2	3.2	3.2
Full-time student	1.9	2.0	1.8
Retired	24.7	24.1	25.9
Disabled due to asthma	6.5	6.9	5.9
Disabled due to non-asthma condition	6.2	5.2	8.1
Unemployed	6.5	6.2	7.2
Missing	3.4	2.7	4.8
Subspecialist care, %			
Allergist/immunologist	38.1	40.2	33.9
Pulmonologist	53.2	50.4	59.1

Allergist/immunologist and pulmonologist	8.6	9.4	6.9
Screening/enrollment treatment class ^b , %			
Uncontrolled on high-dose ICS/LABA only	30.2	27.8	35.3
Any monoclonal antibody	65.3	68.2	59.4
omalizumab	27.8	30.2	23
non-omalizumab	36.6	37.7	34.3
Systemic corticosteroids or immunosuppressant only	11.5	11.3	12.1

^aPercentages may not sum to 100% due to rounding.

^bIncludes Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and Other.

^cOther insurance including other government insurance.

Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting beta agonists; PRO, patient-reported outcome; SD, standard deviation; SGRQ, St. George's Respiratory Questionnaire.